Advaxis, Inc. (NASDAQ:ADXS) price target set to $2.00 by HC Wainwright

ME Staff
-
0

Analyst Ratings For Advaxis, Inc. (NASDAQ:ADXS)

Today, HC Wainwright set its price target on Advaxis, Inc. (NASDAQ:ADXS) to $2.00 per share.

There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Advaxis, Inc. (NASDAQ:ADXS) is Buy with a consensus target price of $3.00 per share, a potential 454.73% upside.

Some recent analyst ratings include

  • 6/13/2018-Advaxis, Inc. (NASDAQ:ADXS) gets downgraded to Hold by Jefferies Financial Group with a price target of $2.00


  • On 11/2/2018 Robert Petit, Insider, sold 8,491 with an average share price of $0.56 per share and the total transaction amounting to $4,754.96.
  • On 9/11/2018 Roni Appel, Director, bought 33,333 with an average share price of $1.20 per share and the total transaction amounting to $39,999.60.
  • On 4/2/2018 Robert Petit, Insider, sold 2,193 with an average share price of $1.62 per share and the total transaction amounting to $3,552.66.
  • On 2/2/2018 Anthony A Lombardo, CEO, sold 32 with an average share price of $2.93 per share and the total transaction amounting to $93.76.
  • On 1/3/2018 Sara Bonstein, CFO, sold 5,224 with an average share price of $3.18 per share and the total transaction amounting to $16,612.32.
  • On 11/6/2017 Robert Petit, Insider, sold 3,723 with an average share price of $3.30 per share and the total transaction amounting to $12,285.90.
  • On 11/6/2017 Sara Bonstein, CFO, sold 3,862 with an average share price of $3.30 per share and the total transaction amounting to $12,744.60.

About Advaxis, Inc. (NASDAQ:ADXS)
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Recent Trading Activity for Advaxis, Inc. (NASDAQ:ADXS)
Shares of Advaxis, Inc. closed the previous trading session at 0,54 −0,023 4,13 % with 0.53 shares trading hands.